Seagen Inc. (formerlySeattle Genetics, Inc.) is an Americanbiotechnology company focused on developing and commercializing innovative, empoweredmonoclonal antibody-based therapies for the treatment of cancer. The company, headquartered inBothell, Washington (a suburb ofSeattle), is the industry leader inantibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris (brentuximab vedotin)[3] is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program[4]to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration withTakeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.
In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes enfortumab vedotin, being co-developed with Astellas Pharma, tisotumab vedotin, being co-developed with Genmab, SGN-LIV1A, an ADC targeting LIV-1, and several immuno-oncology agents in phase 1 studies.
In January 2018, the company announced it would acquire Cascadian Therapeutics for $614 million.[5]
In September 2020,Merck & Co announced it would purchase $1 billion of Seagen's common stock, with both companies co-developing lead treatment:ladiratuzumab vedotin.[6]
In November 2022, the company announced the appointment of David R. Epstein as Chief Executive Officer and Director.[7]
Seattle Genetics has collaboration agreements with Takeda Oncology Company (formerly Millennium) to develop and commercialize brentuximab vedotin. The company also has collaboration agreements for their ADC technology with a number of biotechnology and pharmaceutical companies, includingAbbVie,Bayer Celldex Therapeutics, Inc.,Daiichi Sankyo,Genentech, Inc.,GlaxoSmithKline,Pfizer, Inc., and PSMA Development Company LLC, as well as ADC co-development agreements with Agensys, Inc., an affiliate ofAstellas Pharma, and Oxford BioTherapeutics Ltd.[9]
Seattle Genetics' proprietarymonomethyl auristatin E or MMAE-based antibody-drug conjugate technology, employed in brentuximab vedotin, empowers monoclonal antibodies to treat cancer. Brentuximab vedotin, for example, links the chimeric anti-CD30 monoclonal antibody (cAC10) via a protease-cleavable linker to MMAE. This ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. This approach is intended to spare non-targeted (healthy) cells and thus reduce many of the toxic effects of traditional chemotherapy while potentially enhancing antitumor activity. (See alsovedotins)
Seattle Genetics was founded in 1997, by Henry Perry Fell, Jr.[10] and Clay Siegall,[11] and is headquartered in Bothell, Washington, a suburb of Seattle. The company completed an initial public offering in March 2001, and prior to its acquisition by Pfizer, it was traded on the Nasdaq Stock Market under the symbol SGEN, and was a component of theNasdaq-100. As of December 2016, the company has more than 900 employees throughout the United States.[12][13]
21 December: announcement of new collaboration withGlaxoSmithKline ($12 million up front payment, up to $390 million in milestone payments)[23]
In 2009, when it appeared thatADCETRIS could reach the market, the company realized that commercial skills would need to be grown in-house and/or acquired.[11] This led to a decision to grow a commercial team to address the United States and Canadian markets, and a marketing collaboration withTakeda to cover the rest of the world.[11] By 2018, however, the company was confident it could conduct a global commercialization venture.[11]
6 January: entry into collaboration withPfizer ($8 million upfront payment, $200+ million in potential milestone payments)[34]
1 March: initiation of Phase I clinical trial ofbrentuximab vedotin for use in conjunction with chemotherapy for treatment of systemic anaplastic large cell lymphoma[35]
22 March: announcement of collaboration withAbbott ($8 million upfront payment, plus potential royalties and milestone payments)[37]
11 April: James Fan, SG manager of clinical programming, commits suicide one day after being indicted forinsider trading in Seattle Genetics securities[38][39]
19 April: expansion of collaboration withGenmab[40]
4 June: interim Phase I data from ASG-5ME in prostate cancer[45]
5 July: initiation of global Phase III trial ofADCETRIS againstCD30-expressing cutaneousT-cell lymphoma[46]
24 August: initiation of Phase Ib trial of SGN-75 (INN: vorsetuzumab mafodotin) for use in combination witheverolimus in patients withrenal cell carcinoma[47]
9 October: milestone achievement under collaboration withGenentech by advancements of two antibody conjugates into Phase II trials[48]
29 September: brentuximab vedotin was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.[61]
8 December: Data of Brentuximab Vedotin in Diffuse Large B-cell Lymphoma presented at the Annual Meeting of the American Society of Hematology[62]
12 January: clinical collaboration withBristol-Myers Squibb to evaluate combination of brentuximab vedotin and nivolumab in hematologic malignancies[63]
18 February: Supplemental Biologics License Application (BLA) for Brentuximab Vedotin in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse[64]
8 June: collaboration with Unum Therapeutics to develop and commercialise its new antibody-coupled T-cell receptor (ACTR) therapies for cancer, generating up to $645 million for Unum.[65]
31 December: Adcetris sales increase to $226 million.[66]
In July the press reported Merck & Co. was in advanced talks to acquire Seagen Inc. and was aiming to finalize a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $40 billion or more.[69] The expected sellout is expected to materialize in the month of August 2022 with some delay due to Merck being set to report its fiscal second-quarter earnings on July 28.[70]
In March 2023,Pfizer agreed to acquire Seagen for a total enterprise value of around $43billion. The acquisition includes the FDA approved medicinesAdcetris for lymphomas,Padcev for bladder cancers,Tivdak for cervical cancer andTukysa for breast and colorectal cancers as well as Seagen's drug development pipeline.[8]
Pfizer later announced that it would abandon its plans to build a large manufacturing facility inEverett, Washington, which was scheduled to open in 2024.[71][72]
ASG-5ME: product candidate for the treatment of solid tumours (targetsSLC44A4 in pancreatic, prostate and gastric cancer).
Enfortumab vedotin (aka ASG-22ME, formerly ASG-22M6E): product candidate for the treatment of solid tumours (targets Nectin-4 in bladder, breast, lung and pancreatic cancer);[75][76] developed in 50-50 partnership withAstellas[11]
^Philippidis, Alex (26 September 2016)."Top 25 Biotech Companies of 2016".Genetic Engineering & Biotechnology News. Mary Ann Liebert. Retrieved23 December 2019.
US$1.96 billion (2022)
US$3.67 billion (2022)
